



GLAND PHARMA LIMITED

May 18, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions for the half-year ended March 31, 2023

In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find enclosed the disclosure on related party transactions for the half year ended March 31, 2023.

This is for your information and records.

Yours truly,

For Gland Pharma Limited

P Sampath Kumar
Company Secretary and Compliance Officer

Encl: As mentioned above.

Regd. Office:

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:

Plot No. 11 & 84, TSIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999

GLAND PHARMA LIMITED

Disclosure of related party transactions for the half-year ended March 31, 2023

(Rs. In million)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S.No.	Details of the party (listed entity/subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at September 30, 2022)	Closing balance (As at March 31, 2023)	Nature of indebtedness (loan/ issuance of deb/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Gland Pharma Limited	Gland Pharma International Pte Ltd.	Subsidiary	Sale of goods	3,000.00	1,601.13	609.79	1,352.83	-	-	-	-	-	-	-	-
2	Gland Pharma Limited	Gland Pharma USA Inc.	Step-down Subsidiary	Selling and business promotion expenses	50.00	33.12	-	(27.55)	-	-	-	-	-	-	-	-
3	Gland Pharma Limited	Fosun Pharma USA Inc.	Fellow subsidiary	Advance for supply of goods	-	-	(8.54)	(9.56)	-	-	-	-	-	-	-	-
4	Gland Pharma Limited	Fosun Pharma USA Inc.	Fellow subsidiary	Sale of goods	2,500.00	1,190.12	633.42	613.02	-	-	-	-	-	-	-	-
5	Gland Pharma Limited	Fosun Pharma USA Inc.	Fellow subsidiary	Sale of service	271.32	61.75	101.69	61.64	-	-	-	-	-	-	-	-
6	Gland Pharma Limited	Fosun Pharma USA Inc.	Fellow subsidiary	Reimbursement of expense	110.00	81.03	-	-	-	-	-	-	-	-	-	-
7	Gland Pharma Limited	Jaingsu Wambang Helios International Trade Co. Ltd.	Fellow subsidiary	Advance for supply of goods	-	-	(0.03)	(0.03)	-	-	-	-	-	-	-	-
8	Gland Pharma Limited	Jaingsu Wambang Helios International Trade Co. Ltd.	Fellow subsidiary	Sale of goods	50.00	8.00	-	-	-	-	-	-	-	-	-	-
9	Gland Pharma Limited	Shanghai Fosun Pharmaceutical (Group) Co.Ltd	Fellow subsidiary	Purchase of Services	125.00	50.53	-	(4.53)	-	-	-	-	-	-	-	-
10	Gland Pharma Limited	Suzhou Erye Pharmaceutical Co. Ltd.	Fellow subsidiary	Purchase of raw material	1,628.55	93.42	-	-	-	-	-	-	-	-	-	-
11	Gland Pharma Limited	Tridem Pharma SAS	Fellow subsidiary	Sale of goods	1,500.00	25.18	-	5.18	-	-	-	-	-	-	-	-
12	Gland Pharma Limited	Wambang Biopharmaceutical Company Limited	Fellow subsidiary	Purchase of raw material	4,312.00	767.45	121.33	-	-	-	-	-	-	-	-	-
13	Gland Pharma Limited	Srinivas Sadu	Key management personnel	Remuneration	70.67	36.36	(7.76)	(2.90)	-	-	-	-	-	-	-	-
14	Gland Pharma Limited	Ravi Shekhar Mitra	Key management personnel	Remuneration	18.73	9.22	(2.10)	(0.78)	-	-	-	-	-	-	-	-
15	Gland Pharma International Pte Ltd.	Ravi Shekhar Mitra	Key management personnel	Remuneration	0.74	0.74	-	-	-	-	-	-	-	-	-	-
16	Gland Pharma Limited	Satyanarayana Murthy Chavali	Key management personnel	Sitting fee	0.80	0.50	(0.10)	-	-	-	-	-	-	-	-	-
17	Gland Pharma Limited	Satyanarayana Murthy Chavali	Key management personnel	Commission	2.50	1.25	(1.25)	(2.25)	-	-	-	-	-	-	-	-
18	Gland Pharma Limited	Yiu Kwan Stanley Lau	Key management personnel	Sitting fee	0.80	0.50	(0.10)	(0.28)	-	-	-	-	-	-	-	-
19	Gland Pharma Limited	Yiu Kwan Stanley Lau	Key management personnel	Commission	4.94	2.50	(2.44)	(3.39)	-	-	-	-	-	-	-	-
20	Gland Pharma Limited	Udo J. Vetter	Key management personnel	Sitting fee	0.80	0.50	(0.10)	(0.07)	-	-	-	-	-	-	-	-
21	Gland Pharma Limited	Udo J. Vetter	Key management personnel	Commission	2.50	1.25	(1.25)	(1.72)	-	-	-	-	-	-	-	-
22	Gland Pharma Limited	Essaji Goolam Vahanvati	Key management personnel	Sitting fee	0.80	0.40	(0.10)	-	-	-	-	-	-	-	-	-
23	Gland Pharma Limited	Essaji Goolam Vahanvati	Key management personnel	Commission	2.50	1.25	(1.25)	(2.25)	-	-	-	-	-	-	-	-
24	Gland Pharma Limited	Nainalal Kidwai	Key management personnel	Sitting fee	0.80	0.50	(0.10)	-	-	-	-	-	-	-	-	-
25	Gland Pharma Limited	Nainalal Kidwai	Key management personnel	Commission	10.00	5.00	(5.00)	(9.00)	-	-	-	-	-	-	-	-
26	Gland Pharma Limited	P. Sampath Kumar	Key management personnel	Remuneration	5.08	2.57	(0.46)	(0.17)	-	-	-	-	-	-	-	-
	Total				13,668.53	3,974.27	1,435.65	1,968.18								

Notes

- Amount in bracket denotes credit balance.
- The value of transactions approved, in case of omnibus approval granted by the Audit Committee, are for the financial year 2022-23
- All above transactions are in the ordinary course of business and on arms' length basis. All outstanding balances are to be settled in cash and are unsecured.
- The remuneration to key managerial person does not include the provision made for gratuity and compensated absences, as they are on actuarial basis for the Company as a whole.

For GLAND PHARMA LIMITED



P. SAMPATH KUMAR
Company Secretary